<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> announces preclinical success for EDIT401 with over 90 percent LDL cholesterol reduction in animal models
Editas Medicine Inc. has announced preclinical proof-of-concept data for its experimental therapy EDIT-401, which is designed to significantly reduce LDL-cholesterol (LDL-C). The results were presented at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress. In preclinical studies involving non-human primates and mouse models, EDIT-401 achieved a mean reduction of at least 90% in LDL-C levels following a single dose, with effects maintained in mouse models over a three-month period. The therapy uses a CRISPR/Cas9-based approach to upregulate the LDL receptor (LDLR) by disrupting negative regulatory elements, leading to increased LDLR protein in the liver. The results were shared in an oral presentation by Editas Medicine's Chief Scientific Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9542614-en) on October 09, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。